# Table of Contents

## Highlights

<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Antitumor Efficacy of PD-1 Blockade</td>
</tr>
<tr>
<td>2023</td>
<td>Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2</td>
</tr>
<tr>
<td>2034</td>
<td>Targeted Radionuclide Therapy in Patient-Derived Xenografts Using $^{177}$Lu-EB-RGD</td>
</tr>
</tbody>
</table>

## Review

<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1959</td>
<td>Ion Channels and Their Role in the Pathophysiology of Gliomas</td>
</tr>
</tbody>
</table>

## Small Molecule Therapeutics

<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1970</td>
<td>Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo</td>
</tr>
<tr>
<td>1992</td>
<td>The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA</td>
</tr>
<tr>
<td>2001</td>
<td>Targeting the Synthetic Vulnerability of PTEN-Deficient Glioblastoma Cells with MCL1 Inhibitors</td>
</tr>
</tbody>
</table>

## Large Molecule Therapeutics

<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2044</td>
<td>Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downregulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis</td>
</tr>
<tr>
<td>2057</td>
<td>Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients</td>
</tr>
</tbody>
</table>

---

*October 1, 2020 | Volume 19 | Number 10*
# TABLE OF CONTENTS

## 2068
**PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers**
Adnan O. Abu-Yousif, Donna Cvet, Melissa Gallery, Paul Riviere, Aaron M. Goodman, Ryosuke Okamura, Marije B. Overdijk, Kristin Strumane, Hans Peter Gerber, and Puja Supra

## 2079
**Preclinical Antitumor Activity and Biodistribution of a Novel Anti-NGC Antibody–Drug Conjugate in Patient-derived Xenografts**

## 2089
**Development of Anti-COD2b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies**

## 2105
**Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody**
Amir A. Al-Khami, Sawsan Youssef, Yasmina Abdicbe, HoangKim Nguyen, Joyce Chou, Christopher R. Kimberlin, Sherman M. Chin, Kris Kamperschroer, Bart Jessen, Brent Kern, Natalija Budimir, Christopher P. Dillon, Allison Xu, Jerry D. Clark, Jeffrey Chou, Eugenia Kraynov, Arvind Rajpal, John C. Lin, and Shahram Salek-Ardakani

## 2117
**Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate**

## 2126
**Dual Epitope Targeting and Enhanced Hexamerization by DRS Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DRS Agonism**

## 2139
**High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naive Patients with Diverse Cancers**
Paul Riviere, Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzanna Lee, Noor Khalid, Rachel Collier, Manvita Mareboina, Garrett M. Frampton, David Fabrizio, Andrew B. Shabari, Shumei Kato, and Razelle Kurzrock

## 2146
**Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib**
Yingmiao Liu, Jing Lyu, Kirsten Bell Burdett, Alexander B. Sibley, Ace J. Hatch, Mark D. Starr, John C. Brady, Kelli Hammond, Federica Marmorino, Daniele Rossini, Richard M. Goldberg, Alfredo Falcone, Chiara Cremolini, Kouros Owzar, Anastasia Ivanova, Dominic T. Moore, Michael S. Lee, Hanna K. Sanoff, Federico Innocenti, and Andrew B. Nixon

## 2155
**Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors**
E. Gabriela Chiorlean, Susan M. Perkins, R. Matthew Strother, Anne Younger, Jennifer M. Funk, Saif G. Shahda, Noah M. Hahn, Kumar Sandrasegaran, David R. Jones, Todd C. Skaar, Bryan P. Schneider, Christopher J. Sweeney, and Daniela E. Matei

## 2163
**Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy**
Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy

The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma

Dysregulation of EAAT2 and VGLUT2 Spinal Glutamate Transports via Histone Deacetylase 2 (HDAC2) Contributes to Paclitaxel-induced Painful Neuropathy
Xiao-Min Wang, Pan Gu, Leorey Saligan, Michael Iadarola, Stanley Sau Ching Wong, Lian Kah Ti, and Chi Wai Cheung

Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer
Yoshihisa Kawai, Kenjiro Imada, Shusuke Akamatsu, Fan Zhang, Roland Seiler, Tetsutaro Hayashi, Jeffrey Leong, Eliana Beraldi, Neetu Saxena, Alexander Kretschmer, Htoo Zarni Oo, Alberto Contreras-Sanz, Hideyasu MatsuMama, Dong Lin, Ladan Fazli, Colin C. Collins, Alexander W. Wyatt, Peter C. Black, and Martin E. Gleave

Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis
Joy M. Gary, John K. Simmons, Jinfen Xu, Shuling Zhang, Tyler J. Peat, Nicholas Watson, Benjamin J. Gamache, Ke Zhang, Alexander L. Kovalchuk, Aleksandra M. Michalowski, Jin-Qiu Chen, Tuddow Thaiwong, Matti Kiupel, Snehal Gaikwad, Maudeline Etienne, R. Mark Simpson, Wendy Dubois, Joseph R. Testa, and Beverly A. Mock

ABSTRACT
In this issue of Molecular Cancer Therapeutics, Vijayaraghavan and colleagues outline the mechanism of an anti-EGFR/anti-cMET bispecific antibody, Amivantamab. The anti-tumor efficacy of amivantamab required the Fc-dependent trogocytosis, pictured on our cover. In trogocytosis, macrophages (shown in green) acquired fragments of opsonized tumor cell membranes (shown in orange). Read the full article on page 2044.